
Inflammation and Cardiometabolic Disease Edition: Hepatic Inflammation and Metabolic Dysfunction-Associated Steatohepatitis (MASH)
11/14/24 • 30 min
Host: Darryl S. Chutka, M.D. [@chutkaMD]
Guest: Alina M. Allen, M.D., M.S.
Fat deposits in the liver are quite common and many individuals have no idea they have the condition. A minority of those individuals will develop an associated hepatic inflammation. It’s not entirely clear why some progress to this state, although there are some known risk factors. Steatohepatitis is a potentially serious health problem and can lead to end-stage liver disease. It’s also associated with cardiovascular disease and all of its complications. The topic for today’s podcast is Hepatic Inflammation and Metabolic Dysfunction-Associated Steatohepatitis. My guest is Alina M. Allen, M.D., M.S., from the Division of Gastroenterology and Hepatology at the Mayo Clinic. What are the risk factors for this health problem? Should we be screening patients for its presence and how should it be managed. These are just some of the topics we’ll discuss in this podcast.
These talks on Inflammation and Cardiometabolic Disease are sponsored by Novo Nordisk
Learn more about this series HERE
Connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd.
Host: Darryl S. Chutka, M.D. [@chutkaMD]
Guest: Alina M. Allen, M.D., M.S.
Fat deposits in the liver are quite common and many individuals have no idea they have the condition. A minority of those individuals will develop an associated hepatic inflammation. It’s not entirely clear why some progress to this state, although there are some known risk factors. Steatohepatitis is a potentially serious health problem and can lead to end-stage liver disease. It’s also associated with cardiovascular disease and all of its complications. The topic for today’s podcast is Hepatic Inflammation and Metabolic Dysfunction-Associated Steatohepatitis. My guest is Alina M. Allen, M.D., M.S., from the Division of Gastroenterology and Hepatology at the Mayo Clinic. What are the risk factors for this health problem? Should we be screening patients for its presence and how should it be managed. These are just some of the topics we’ll discuss in this podcast.
These talks on Inflammation and Cardiometabolic Disease are sponsored by Novo Nordisk
Learn more about this series HERE
Connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd.
Previous Episode

Inflammation and Cardiometabolic Disease Edition: hs-CRP and Cardiovascular Disease
Host: Darryl S. Chutka, M.D. [@chutkaMD]
Guest: Regis I. Fernandes, M.D.
Inflammation commonly occurs as a response to injury or infection but can lead to damage when it develops in healthy tissue. It’s now known that inflammation plays a key role in the development of cardiovascular disease. It produces damage to the endovascular arterial cells allowing plaque to form within the artery leading to stenosis, thereby reducing coronary blood flow. What initiates the inflammatory response as it develops in otherwise healthy arteries? How should we use the hs-CRP in measuring inflammation in cardiovascular disease? Does our management of cardiovascular disease result in a decrease in hs-CRP? These are some of the questions I’ll be asking my guest, Regis I. Fernandes, M.D., a preventive cardiologist from the Mayo Clinic as we discuss “hs-CRP and Cardiovascular Disease”.
These talks on Inflammation and Cardiometabolic Disease are sponsored by Novo Nordisk
Learn more about this series HERE
Connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd.
Next Episode

Inflammation and Cardiometabolic Disease Edition: Obesity - The Linking Pathology
Host: Darryl S. Chutka, M.D.
Guest: Maria L. Collazo-Clavell, M.D.
Its common knowledge that those who are obese are at greater risk for developing metabolic syndrome, diabetes and cardiovascular disease. However, the reason for this association has not always been clear. It does appear that systemic inflammation plays a major role and obesity triggers this inflammation. But what specifically initiates the inflammation? How can we measure it? Most importantly, can we reduce or eliminate this inflammation and prevent the progression to these cardiometabolic states? My guest for this podcast is Maria L. Collazo-Clavell, M.D., from the Division of Endocrinology and Metabolism at the Mayo Clinic and we’ll discuss “Inflammation and Cardiometabolic Disease: Obesity- The Linking Pathology”.
These talks on Inflammation and Cardiometabolic Disease are sponsored by Novo Nordisk
Learn more about this series HERE
Connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd.
If you like this episode you’ll love
Episode Comments
Generate a badge
Get a badge for your website that links back to this episode
<a href="https://goodpods.com/podcasts/mayo-clinic-talks-342276/inflammation-and-cardiometabolic-disease-edition-hepatic-inflammation-78256656"> <img src="https://storage.googleapis.com/goodpods-images-bucket/badges/generic-badge-1.svg" alt="listen to inflammation and cardiometabolic disease edition: hepatic inflammation and metabolic dysfunction-associated steatohepatitis (mash) on goodpods" style="width: 225px" /> </a>
Copy